Go back

Inflammatory Neuropathies Series: Paraneoplastic peripheral nerve disorders

33m 51s

Inflammatory Neuropathies Series: Paraneoplastic peripheral nerve disorders

Paraneoplastic neuropathies are immune-mediated disorders linked to underlying cancers, with no single diagnostic hallmark. Clinical suspicion arises from rapid, asymmetric, or non-linear sensory neuropathy, autonomic dysfunction, or coexisting CNS involvement. Key red flags include sensory ganglionopathy, GI obstruction, and peripheral hyperexcitability. Cancer associations—such as small cell lung cancer with anti-Hu or anti-Caspr2 antibodies—help direct diagnosis and screening. Electrophysiology is vital for phenotypic characterization, while antibody testing must be interpreted cautiously due to false positives or low titers. The PNS Care Score offers a practical diagnostic tool, enabling probable diagnosis even without antibody positivity. Treatment depends on the antibody type: cell surface antibodies respond to immunotherapy (e.g., steroids, plasma exchange), whereas intracellular targets involve cytotoxic T-cell damage with poor recovery. Early diagnosis and timely intervention—especially within the first year—are crucial for improved outcomes. Management requires close collaboration between neurology and oncology, especially when balancing cancer therapy with immune-related adverse events like those from checkpoint inhibitors. These novel therapies, including antibody-drug conjugates and CAR-T, introduce new neurotoxic risks, necessitating ongoing vigilance. Ultimately, the cornerstone of care is phenotypic assessment first, guiding all diagnostic and therapeutic decisions to ensure accurate patient management.

Transcription

5088 Words, 32431 Characters

English
Hello and welcome to the peripheral nerve podcast. The official podcast of the peripheral nerve society. Together, we implore topics in peripheral nerve disorders, awareness, education and advocacy. This series covers inflammatory neuropathies. I am Hebatala Roshent, professor of neurology at the Enchants University in Cairo, Egypt, co-hosting this series with my colleague. Where to be Lanti, I'm a clinic lecturer in neurology at the University of Oxford. We are delighted to be interviewing Dr. DeVianche Dubay to discuss the topic of Paranyu Plastic Nerve Disorders. Welcome to our podcast and please dev introduce yourselves to our listeners. Thank you Hebander Lovatov. It's a pleasure to be here and thank you for inviting me to the peripheral nerve podcast. I'm DeVianche Dubay. I'm a professor of neurology, lab medicine and pathology and a co-director of the Nerve analogy lab here at Mayo Clinic Rochester. My clinical and research work focuses on autoimmune and perineoplastic neurological disorders including neuropathies, with a particular interest in neural auto antibodies, discovery, testing for a clinical lab and their clinical interpretation. This is an area I'm very passionate about and I'm delighted to join you both for further discussion on this topic. Thanks DeVianche for accepting our invitation and we are very excited to discuss this topic with you because that notion of these rare disorders can be quite challenging. As we all know, Paranyu Plastic neurologic syndrome are remote effects of cancer with immune-meditated pathogenesis. The recognition of these disorders and their oncological associations is crucial as early diagnosis and management have been associated with better outcomes. Today, we are looking forward to learning from Dr. Dubay's expertise as we navigate this topic. So, that's my first question. What are the red flags that make you suspect Paranyu Plastic cause underlying certain neuropathy? Is there maybe a pathognomonic clinical presentation or something? It's a great question. I think the most important thing we need to recognize is there's not a single pathognomic neuropathy phenotype that tells us that this is Paranyu Plastic. What raises my suspicion, as I'm seeing patients in our peripheral nerve, is usually a combination of things. So, the tempo of presentation, how fast the things are progressing, the clinical phenotype, associated neurological features such as co-existing CNS involvement, autonomic dysfunction in some of these cases, and then the patient's cancer risk. A particularly important red flag is usually, as I was saying, a subacute or rapidly progressive painful asymmetric non-linear dependent sensory neuropathy phenotype is something I would probably regard as a highly likely phenotype, which should raise concerns of red flags for underlying Paranyu Plastic autoimmunity. These patients may develop prominent, proprioceptive loss sensory attacks here in what, initially, involving the upper limbs, as well as lower extremities in an atypical non-linear dependent pattern, which again differentiates it from the more common forms of neuropathy, we come across in that chemical disorder. And I was saying, other clues are prominent autonomic dysfunction, gastric GI dysmortality, peripheral nerve-hypics excitability presentations, and then co-existing multifocal neurologic syndromes. So if you're a patient with neuropathy and myelopathy, that's a red flag, or if you're a patient with encephalomyelitis with this, encephalitis along with peripheral manifestations, like a limbic encephalitis of a sensory young neuropathy, that's another potential red flag for Paranyu Plastic autoimmunity. And some of this phenotypic characterization was covered in the update that 2021 PNS diagnostic criteria, which adds the pleasure to be a part of, where we categorize these phenotypes into high-risk, intermediate-risk phenotypes. And some of the important neuropathy or peripheral nerve phenotypes, which were characterized as high-risk phenotypes were sensory ganglenopathy or neuropathy, and GI dysmortality, more significantly GIs into obstruction as high-risk phenotypes. And the intermediate-risk phenotype included manifestations, such as peripheral nerve hyperexcitability, sometimes with co-existing CNS involvement. So those I would use as red flags. Awesome. So I understand from what you said that there is a correlation between antibodies and the clinical presentation. What about the association between certain cancers and the clinical presentation and maybe fiber type involvement? The cancer association certainly influences the phenotype and especially the underlying antibody. But I wouldn't say completely dictate the phenotype. So for example, one of the most common cancers that are typically associated with Paranyu Plastic autoimmunity are neuroendocrine tumors, especially small-cell lung cancer. And often the antibodies that we typically come across in patients with ocular small-cell lung cancers are antibodies such as anti-hue, confirmed five, amphiphysin, PCA2, or MAP1D. Among these cases, the most common clinical phenotype often end up being those high-risk phenotypes I was referring to, especially in cases with anti-hue or an A1 auto-antibodies, or even in some cases with amphiphysin antibodies, which can have existing stiff person-like presentation as well. But in addition to the sensory gagnonopathy phenotype, one phenotype that was added to the updated Paranyu Plastic diagnostic criteria as an intermediate risk phenotype, primarily from some of the work that we had done with Crimp 5 and PCA2 antibodies, what this phenotype called as exonal polyrdiclinoropathy, where these patients were presenting with sensory motor involvement, often with proximal and distal asymmetric presentations, which was found to be one of the most common presentations in Crimp 5. So with small-cell lung cancers, those are the clinical presentations to think about. With thymoma, the picture can be slightly different because this is where we are starting to think about some of the peripheral hyperaccessibility syndrome, but also to address your question about fiber-tie. Some of the small fiber neuropathy info presentations, because thymoma can be associated with Casper 2 as an underlying auto antibody, which can present in the form of ISEX syndrome, which predominates your peripheral neurohyper-peripheral hyperaccessibility presentation, but can also have coexisting peripheral and central involvement in the form of more advanced syndromes, where these patients, along with having neuromytonia, myochymia, have sleep dysfunction and cellopathy and other coexisting CNS features. And some of these Casper 2 cases can also present with predominantly a small fiber neuropathy of phenotype with diffuse pains syndrome. Often these diffuse pain presentations have coexisting features that would help you distinguish them from other more common small fiber neuropathy that we see in our clinic that may include either coexisting CNS involvement or that may include significant dysautonomia to grow along with the pain presentation. Thank you. So how do you distinguish a partner of plastic neuropathy from direct cancer infiltration or the toxicity of cancer treatment? That's a great question. And end up being often asked, more often, especially in inpatient settings, when we have really sick patients, sometimes with metastatic cancers, sometimes patients were receiving immune check fund inhibitors for extended metastatic cancers, where it can be very challenging to pinpoint the exact epiology for their progressive neuropathy. I think the way I usually tackle these challenging cases is similar to what we were talking about in response to the previous questions, starting by doing a careful phenotypic fetic transition. And I think that defined or guide us in terms of what the underlying etiology may be. So again, if you're seeing a high risk phenotype or potentially in some cases, intermediate risk phenotype, such as ganglenopathy or hyperacetabilitis syndrome, that might guide you more towards this is an immune mediated per neuropathetic process, either denoval per neuropathetic, which is purely triggered by cancer. Or in some cases, with use of immune check fund inhibitors, potentially itrogenic where the floodgates have been opened by these drugs, which are subduing the barriers, which prevent us from developing our community. In the cases, which often can be more challenging, are these polyredicular involved, because in certain cancers, there could be cancer infiltration inside the nerve roots, which could have a polyredicular neuropathy presentations. And in those cases, more careful investigations, including spinal tap, in some cases, vesicular biopsies may end up being required for us to cause a certain ordinary etiology, maybe. That's really helpful. Thank you. And you mentioned some of the antibodies commonly included in parlioplastic panels. In real life, we often get no tighter results. And honestly, that can make things more confusing than helpful. So how do you interpret low titers? Another very, very good question. I think even in our practice, sometimes a lot of referrals I get are for patients where the antibody is positive but the phenotype is not. doesn't make sense. And in these are the cases where sometimes unfortunately are being treated for an autoimmune or a palliative plastic disease which they do not have. So when we get an antibody result, it should not be ever interpreted independent of the phenotype of the patient, but also the other questions that are worthwhile to think about are what specimen type was tested, what acid methodology was used, and as you rightly pointed out in certain antibodies, what was the tighter of the antibody. I'll give you some examples. There's a study from Leon which highlighted that patients were positive about their neoplastic antibodies only tested by immunodarts or line blots and were not either tested, were not positive by tissue, immunofluorescence, assay, majority of the patients, in some cases more than 75% of the patients did not have the pallioplastic syndrome, which is a major dirt flag and highlights the importance of potentially sending samples for patients where the phenotype and antibody are not necessarily correlating to a reference lab to potentially get retested or encourage the labs that we are working with to include the most optimal methodology for testing these antibodies, so especially for paranoid plastic antibodies that should include tissue, immunofluorescence, staining in most of the cases. As far as the titers are concerned, they are more relevant for certain antibodies which are being tested by radiomino acids or even alizers, where there could be potential some clinical or analytical factors, which are suggest the higher titers may be more specific. I'll give you an example from sort of the non-pernioplastic realm, there's an antibody called as alpha-3 ganglionic receptor antibody, which were tested by radiomino acids, we have shown that titers above 0.4 nanomoles per meter are the ones which are strongly associated with autoimmune or autonomic dysfunction and lower titers can be non-specifically seen in various diseases. The same can be true for other antibodies such as the TQ type calcium channel antibody associated with lambertate and micethenics syndrome. And then lastly as I was saying, especially for these multifocal manifestations, the specimen type sometimes ends up being useful, we may all be aware that for a LDA serum can generate a lot of false positives, similarly for some of the neuropathy associated with that new scene in patients with GFAP antibodies, which can have a myelotaridiculopathy or a pularidiculonoropathy presentation, testing just serum can sometimes generate false positives, also even specimen type, along with acid methodology, titers ends up being relevant in some of these cases. And I've just added that thing as I was mentioning, the updated pyromioplastic diagnostic criteria is a useful tool where one of the approaches that was suggested was to make the process of diagnosis more pragmatic, even for antibody negative cases, we suggested a scoring system called a pianist care score, which divides the diagnosis into three levels, the clinical, the laboratory, and then the oncology of the cancer level. Even if the antibody is not positive in some of these cases, the clinical phenotype and as you pointed out the cancer detection can lead to a diagnosis of probable pyromioplastic neurological syndrome in some of these cases. Thank you. What about electrophysiological features? Are there any features that are specific to certain pyromioplastic neuropathies or certain cancers as well? Although I don't think there's one electrophysiologic signature which is pathognomic for pyromioplastic neuropathies, I think electrophysiology is extremely useful. As we've been harping on again, the topic of phenotypic characterization in neuropathies that is next to impossible without doing the electrodagnostics, careful electrodagnostics in most of these cases. So that non-linear dependent pattern of presentation that suggests sensory gamutinopathy that comes from carefully electrophysiologic study, the polarity-clone neuropathy phenotype in many of these sort of the crimp-fired cases requires careful electrodagnostic characterization and similarly for studying patients with peripheral hyper excitability syndromes with Casper-2. I'm literally demonstrating my atomic neuron, mytonid discharge is extremely useful. What it also potentially helps us in many of these cases is as a biomarker to assess when to a change when these patients are appropriately diagnosed and then subsequently treated how the patients are changing over time. Are we on the right path as far as the treatment is concerned? Yes, absolutely. What about cancer screening? Once you suspect the pattern of neuropathy, how do you look for the tumor and what do you do is the first screen is negative? So initially you think that the cancer screening is again dictated by the clinical presentation and the probability or the risk associated with the patient's clinical presentation, the specimen information in terms of the probability of having a perineoplastic syndrome, and then the underlying antibody that is detected is also extremely helpful because that can guide what type of cancer to search for. So other than the typical risk stratification that we can do based on the high-res phenotype, the patient's age, the patient's smoking history, the other risk factors. If the patient has antibodies such as antihurana one, then I know I'm looking for in most cases a neuroendocrine tree more specifically small cell lung cancer. If somebody has crimped five antibody along with two antibodies, the combination can guide that the surge should be for underlying thymoma or thymic carcinoma, which could be driving the disease process. Other antibodies such as MART2, which in the past years to be mostly associated with CNS manifestation, we're easily demonstrated can have peripheral manifestations as well, are antibodies that can have seminomas or john certumers as potential triggers. So the detection of antibodies along with the syndromic classification, authentic classification, ends up guiding cancer search. In most of the cases, the cancer surge starts with a CT-based methodologies with CT-just abdomen pelvis and PET scans, especially for high-res phenotypes. Whenever there's concern for there could be an underlying seminoma, it's very important to remember to do a scrotal ultrasound because PET scans usually often miss seminomas. And then in some of these high-risk pernioplastic phenotypes and antibodies, if you don't find a cancer on the initial screen, in those are the cases where I do serial imaging for serial screening for cancers, but actually every six to nine months for the first couple of years, to make sure that no knee cancer is being developed, it could be identified and treated. Well, let's move on to treatment and diagnosis. What do you treat those patients there? And for how long? Yeah, I think the first, I would say we take a step back and start thinking about these diseases pathophysiologically. So these diseases could be simplistically be characterized into antibody mediated or T cell mediated, especially in scenarios where we know the underlying auto antibody target. The serial negative cohorts could be more challenging because that we don't have that additional information that we'll get from antibody. So for cell surface antibody mediated pernioplastic neuropathies are peripheral neurologic manifestations. An example being peripheral nerve hypersetability in the setting of Casper-2 antibodies, that the goal of the treatment focuses on removing that pathogenic antibody from the system. So that could include utilization of plasma exchange early on in the disease course. Often in most of these cases, I like using steroids. If it's an outpatient patient and I can't do it as easily, my first go to regimen ends up being steroids for even cell surface antibodies. And then in these are the cases where medications like retuximab with sort of B-cell population, potentially other medications that can delete the antibody forming or making sources, such as plasma cells, may end up being useful for treating these diseases. And of course, I go without saying you need to take care of the trigger, whatever that underlying tumor is, which is driving the disease process. These are the patients with cell surface antibodies, which tend to be more responsive. And these are the cases where we can hope to bring about considerable improvement over time. The picture is slightly more guarded for the intracellular autoantigens of potentially cytoxicity, cell mediated diseases. And a lot of these pernioplastic neuropathies end up falling into this bucket. So we talked about anti-heural and one associated sensory ganglion apathies, where even though the antibody is extremely useful for the diagnosis, the disease is not being caused by the antibody. The disease is being caused by the cytokethycer, which are going in attacking, possibly the anti-heural antigen being expressed on MHC class one on the surface of the neurons, or in the ganglia, or in the torsoludanglia. Once the teasers have destroyed these neurons, we don't necessarily have means so far to grow them back. So time is critical. Dagnosing these patients early and initiating them on medications such as steroids, such as cyclophosphamide early so that we can suppress this aggressive cellular response is critical for their long-term prognosis, along with taking care of the underlying cancer. What often is challenging as we manage these cases is this back and forth between neurology and oncology. We just recently had a patient with extended stage false lung cancer, who had sense a gangrenopathy required the subgressive immunotherapy regimen. But then as the oncology team was treating the cancer, they wanted to start chemotherapy regimen for the cancer. The chemotherapy regimen put the patient at risk for such significant bone marrow suppression that adding cytoxin on top of it was difficult. So those are cases where you have to work very closely as a multidisciplinary team with your oncology counterparts to come up with the best potential regimen for the patient so we can take care of the trigger, but also the neurological deficits which can be extremely debilitated. And for how long could you treat these patients? So usually for most of these ternia plastic diseases where we think we know the trigger which is causing the disease, early aggressive treatment is most important. But after the early aggressive treatment of the first six months to a year is the time when we start pulling them off treatment. Sometimes it ends up being a year because of this concept that some of these patients, like we've demonstrated to some of the studies we've done in Keltch 11, which is a different 90-body between the ternia plastic central manifestation, which shown that some of these patients want to develop memory t cells which probably lurk around in the system. And even once you remove the tumor, it can continue to cause damage. That's the idea that supports that just stopping the treatment after first few months ends up being not sufficient. So the first year time period of continuation is end of being critical in some of these cases. But six months is the most important period, but often ends up extending to a year. Are there factors that predict a good treatment out, perhaps the type of antibody or tumor? Yes, I think as we were talking about the location of the antigen, so cell surface was the intracellular antibody could be one potential factor that simplistically divides patients into good responders versus cases where the goal is mostly to stabilize the disease rather than bring about significant improvement. And then in addition to that, the clinical phenotype, so some of these multi-focal diseases where the initial disease severity is so severe or so damaging that often times the recovery and the being more guarded or limited is another potential driving factor. And then the third thing as we talked about in the previous discussion is the timing, how soon are we diagnosing these patients and treating these patients? And that ends up being one of the major dictating factors in terms of how they are doing at the end of a year or two years. And then lastly, as you pointed out, malignancy plays a role as well because ultimately, we're not just treating the antibody or the neuropathy or treating the patient who sometimes has very aggressive cancers. And there are scenarios where, because the cancer is aggressive and is at an extended stage, that can be the potential cause for mortality rather than the perineal plastic disease process itself. I think we should also discuss immune checkpoint inhibitors, which have transformed cancer can, but they can also trigger neurological complications, including neuropathies. And I think we all agree that these toxicities are increasingly falling to the neurologist. How do check point inhibitor neuropathies differ from the classical perineal plastic syndromes we've discussed so far? As you already pointed out, this is the kind of fascinating and extremely very challenging area for where all of us deal with. And we see these patients, both in an often an inpatient setting as well as some patients being followed in personal nerve clinics or nerve neuromuscular clinics after they've been discharged. You mean checkpoint inhibitors essentially remove the inhibitory signals for upon the immune system? So they can produce denover neurologic immune related adverse events potentially through various different mechanisms. One of the mechanisms being the patient had this propensity to develop our immunity, but these checkpoints were holding off, development of our immunity. So this is truly an autoimmune process, whereas the other being more sharing more mechanistic similarities with perineal plastic syndrome where the immune system ends up attacking a protein which is expressed by the cancer or the tumor. And that protein is not just expressed in the tumor, but also expressed in the nervous system leading to this potential friendly fire, leading to a disease process which mimics more the classic perineal plastic neurologic syndrome. The peripheral manifestations associated with these immune adverse events end up being slightly more common than the central manifestations, more commonly among the peripheral manifestations end up being myopathies, but we are starting to see more and more neuropathic manifestations as well. And one important thing to remember at these cases is it's often not just the one system which is impacted. These patients can have multifocal or multi-organ involvement. So requiring multidisciplinary care in many of these cases of had patients with GBS-like phenotype who also have pneumonitis or colitis. So you have to take many things into consideration while managing these patients. I think as you rightly pointed out the frequency as one of the phenotypic presentations are growing partly because of includes use of these checkpoint inhibitors, but also growing indications of immune checkpoint inhibitors. I remember when I was doing my fellowship in Boston, most of the cases that we were seeing were in the setting of melanoma because that was one of the first indications and most early clinical files were being done in melanoma with ICI. And the phenotypes that used to come across were more like GBS-like presentations, but also criminal neuropathies with a lot of seventh nerve involvement and other criminal neuropathies as clinical phenotypes. As the indications have now spread to neuroendocrine tumors like mulledine cancer or small external disease, small cell lung cancer, we are starting to see clinical phenotypes that resemble what we were classifying as high risk or in some intermediate risk phenotypes. So we've had quite a few of cases with sensory ganglion apathy, where coexisting and a hue or polyrdical neuropathy with crampified, which triggered in the setting of main checkpoint inhibitors. The presence of the underlying cancer and the associate phenotype and the underlying antibody not only ends up being helpful in understanding the disease biology, it also ends up being super helpful in recognizing how aggressive to be as far as the treatment of these patients are concerned. Many of my patients with phenyl neuropathies or Bell spalsy following ICI were the ones where stopping ICI putting them on steroids led to considerable improvement. Those were scenarios that we could at least entertain the conversation about potential re-challenging the cancer really needed another immune check on inhibitor dose. Unfortunately, some of these thorneoplastic phenotypes like ganglion apathy or GI subobstruction, I personally don't even entertain that idea re-challenge because we've had cases where we have reinitiated immune check on inhibitors and they've succumbed to the immune-related adverse event from the progressive thorneoplastic disease process rather than the cancer. So recognizing even here, recognizing the phenotype, utilizing the antibodies and the being extremely useful in clinical decision making. Yes, and in practice that leads to the question if a patient is responding well to immunotherapy but develops neuropathy then how do you decide whether to stop pause or continue a immune check point in the middle treatment and who makes the call who decides? I think ultimately it requires many the various providers who are seeing the patient to come together to have that frank discussion with the patient in the family to try and understand the potential risks associated with the various outcomes that sort of starting immune check on inhibitors get due to the patient. So I think if there are signs to suggest let's say we're stuck in a scenario where ICIs have not been initiated, but you're seeing a patient with extended stage false lung cancer who's already starting to develop asymmetric non-independent neuropathic presentations and you test for the antibody and anna one aren't a huge positive even though at this stage the deficits are not very significant I would not start that patient on immune check for inhibitors because it in one of our recent studies or studies published a few years ago there were certain cases that were started in the drastically succumbed or worsened within a few weeks to a very aggressive form of perinoplastic disease and this not just been our experience there's been experience among others as well but as in other cases where a patient has neuropathic features but the presentation of neuropathy makes you think that it may be either a neuropathy from an alternative metabolic etiology or could be secondary to the chemotherapy that they were receiving for their cancer before ICI was all being discussed those are the cases where clinical characterization you know to pick acquisition utilization of electrophysiology can guide the discussion and potentially those are the cases where ICIs would make sense especially if the oncology truly believes that can bring about improvement in their cancer. I think that the rechallenge question is also a difficult one as I addressed in the last answer I think that in the patients who have a classic perinoplastic perinoplastic phenotype and high-resperinoplastic antibodies I really urge the oncologists to reconsider and think about alternative ways to manage the case rather than immune re-initiation of immune check on inhibitors in some of the other milder are almost neuropathies a week. that remains an option, that even though, because even though there's a risk of disease relapse, our progression, sometimes the risk of cancer progression is so high, and since the options are not available, that may end up being the answer for these patients. More and more new therapies are coming through, and so we are seeing new oncotherapeutic toxicity as well. So could you tell us about newer treatments, like antibody drug conjugates, and how they cause it pretty from the complication? Yeah, I think the antibody drug conjugates and those other other therapies which are coming in, imputing potential with had cases of CAR-T, associated peripheral manifestations, are making the feel much even more, more interesting, but more complicated, and I think the continuing to remain up to date with various newer modality treatments, which can complicate our clinical practice, remain something we all have to be continuously updated on. I think most of these cases, the pathophysiology is a lot different from what we were thinking of for our perineoplastic syndrome, where this concept of friendly fire or shared antigen expression or immune response, but given that these patients have extended to test cancer and are manifesting these neuropathic presentations, recognizing what phenotypic characterization in antibodies can guide us to rule in or rule out perineoplastic autoimmunity continues to be extremely important. As we wrap this up, that was the most important thing, you want our listeners to take away. I think the most important thing is think about the phenotype first. Ultimately, we are not treating the antibody or other test results. We are treating the patient and most of the time when the patient comes to us, all we can see is the neuropathy presentation, characterizing that carefully, clinically, electrophysiologically, and then guiding the diagnostic workup or management based on that phenotypic characterization is the most crucial aspect of the care we provide to these patients. That not only helps us think about the right kind of tests that need to be sent, for these cases, the potential increase in the pretest probability, but also makes us ready for situations where the test result comes back positive, but the phenotype or the clinical characterization doesn't make sense. It allows us to think about the potential scenarios, what could have be happening that could be generating false positive results, and the subsequent workup and the clinical characterization using modalities such as the PNS Care score can then in turn help us with early diagnosis of these cases, which in turn can guide cancer search and guide early initiation of treatment, which ends up being most crucial. And that's it. These are very helpful tips. Finally, we would like to thank Dr. DuBay for the awesome discussion and for sharing his wisdom with us. Thank you, Dev. Thank you, Eber and Roberto. Thank you for inviting me for this podcast, wonderful discussing this video. Thanks for listening and see you next month. The primary purpose of the peripheral nerve podcast is to meet the educational needs of its listeners and address practice gaps by providing practice oriented and scientifically-based education that will maintain an advanced competence and performance in the peripheral nerve field. A diversity of opinions exists in the medical field and the views of the podcast faculty do not represent those of the peripheral nerve society or constitute an endorsement by the peripheral nerve society.

Podcast Summary

Key Points:

  1. Paraneoplastic neuropathies lack a single pathognomonic presentation, but red flags include rapidly progressive, asymmetric, non-linear dependent sensory neuropathy with prominent autonomic dysfunction or CNS involvement.
  2. Specific cancer associations—such as small cell lung cancer with anti-Hu or anti-Caspr2 antibodies—guide phenotype and diagnostic suspicion, with high-risk phenotypes like sensory ganglionopathy and GI obstruction being key indicators.
  3. Electrophysiology is essential for phenotypic characterization, revealing patterns like non-linear dependent sensory loss or peripheral hyperexcitability that distinguish paraneoplastic from other neuropathies.
  4. Antibody testing must be interpreted in context
  5. The PNS Care Score provides a pragmatic diagnostic framework, enabling probable diagnosis even in antibody-negative cases by integrating clinical, laboratory, and oncological factors.
  6. Treatment strategies differ by antibody type—cell surface antibodies (e.g., Caspr2) respond well to plasma exchange and steroids, while intracellular targets (e.g., anti-Hu) involve cytotoxic T-cell-mediated damage with limited recovery.
  7. Early diagnosis and aggressive intervention (especially within the first 6–12 months) are critical, with some patients requiring long-term monitoring due to persistent immune memory or delayed relapse.
  8. Immune checkpoint inhibitors can trigger neuropathies mimicking paraneoplastic syndromes, requiring multidisciplinary management and careful risk-benefit analysis before re-challenging therapy.

Summary:

Paraneoplastic neuropathies are immune-mediated disorders linked to underlying cancers, with no single diagnostic hallmark. Clinical suspicion arises from rapid, asymmetric, or non-linear sensory neuropathy, autonomic dysfunction, or coexisting CNS involvement. Key red flags include sensory ganglionopathy, GI obstruction, and peripheral hyperexcitability.

Cancer associations—such as small cell lung cancer with anti-Hu or anti-Caspr2 antibodies—help direct diagnosis and screening. Electrophysiology is vital for phenotypic characterization, while antibody testing must be interpreted cautiously due to false positives or low titers. The PNS Care Score offers a practical diagnostic tool, enabling probable diagnosis even without antibody positivity.

, steroids, plasma exchange), whereas intracellular targets involve cytotoxic T-cell damage with poor recovery. Early diagnosis and timely intervention—especially within the first year—are crucial for improved outcomes. Management requires close collaboration between neurology and oncology, especially when balancing cancer therapy with immune-related adverse events like those from checkpoint inhibitors.

These novel therapies, including antibody-drug conjugates and CAR-T, introduce new neurotoxic risks, necessitating ongoing vigilance. Ultimately, the cornerstone of care is phenotypic assessment first, guiding all diagnostic and therapeutic decisions to ensure accurate patient management.

FAQs

Red flags include a rapidly progressive, asymmetric, non-linear dependent sensory neuropathy, prominent autonomic dysfunction, co-existing CNS involvement, and specific symptoms like gastrointestinal obstruction. High-risk phenotypes such as sensory ganglionopathy or GI dysmotility are particularly concerning.

Certain antibodies like anti-Hu, anti-CRMP5, or anti-MART2 are associated with specific clinical features. For example, anti-Hu is linked to small cell lung cancer and sensory ganglionopathy, while anti-CRMP5 can present with exudative polyneuropathy with sensory-motor involvement.

Phenotypic characteristics such as sensory ganglionopathy or peripheral hyperexcitability help differentiate. If the neuropathy is rapidly progressive with multifocal features, it's more likely paraneoplastic. Imaging and biopsy may be needed if cancer infiltration is suspected.

Antibody results should never be interpreted in isolation from the clinical phenotype. Low titers or negative results do not rule out paraneoplastic disease, especially if the patient has a high-risk clinical presentation. Tissue immunofluorescence and optimal testing methodologies are crucial.

Electrophysiology helps characterize the neuropathy pattern—such as non-linear dependent sensory neuropathy or peripheral hyperexcitability—supporting phenotypic classification. It is essential for guiding diagnosis and monitoring treatment response.

Screening starts with CT abdomen/pelvis and PET scans, guided by the antibody profile. Anti-Hu suggests small cell lung cancer; anti-CRMP5 suggests thymoma. If initial screening is negative, serial imaging every 6–9 months is recommended for up to two years.

Chat with AI

Loading...

Pro features

Go deeper with this episode

Unlock creator-grade tools that turn any transcript into show notes and subtitle files.